文献速递腹部介入CT

CT引导经皮射频消融治疗肾上腺转移瘤的有效性与安全性

Effectiveness and safety of CT-guided percutaneous radiofrequency ablation of adrenal metastases.
PubMed 文献 · Br J Radiol · 2018-03-07

回顾性分析2012至2015年33例患者38个肾上腺转移瘤接受CT引导经皮射频消融,平均直径3.0±1.6 cm,技术成功率78.9%(30/38),残留病灶率18.9%(7/37),肿瘤<3 cm组残留率显著低于≥3 cm组(p=0.025),严重并发症率4.3%,随访27.4个月无复发生存率76.3%。

要点

  • CT引导经皮射频消融肾上腺转移瘤技术成功率78.9%(30/38),残留病灶率18.9%(7/37)。
  • 肿瘤<3 cm组残留病灶率显著低于≥3 cm组(p=0.025)。
  • 严重并发症率4.3%,轻度并发症率48%,术中高血压危象最常见(27.3%)。

核心结论

  • 射频消融是控制肾上腺转移瘤相对安全有效的治疗方法,尤其适用于肿瘤<3 cm的患者。

研究设计与样本

  • 回顾性研究,纳入2012至2015年33例患者共38个肾上腺转移瘤,接受CT引导经皮射频消融,平均直径3.0±1.6 cm,每3个月随访监测疾病进展。

关键影像表现/征象

  • 术后CT显示30个肿瘤(30/38)无肿瘤强化,技术成功率78.9%。
  • 7个肿瘤(7/37)发现残留病灶,残留病灶率18.9%。

诊断标准与关键数值

  • 技术成功定义为术后CT显示肿瘤无强化,技术成功率78.9%(30/38)。
  • 残留病灶率18.9%(7/37),肿瘤<3 cm组残留病灶率显著低于≥3 cm组(p=0.025)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The imaging-guided percutaneous radiofrequency (RF) ablation of adrenal metastases is a relatively new treatment procedure, compared to the more widespread application of the technique for the treatment of liver and renal cancers. The present study aims to evaluate the safety and efficacy of the CT-guided percutaneous RF ablation of adrenal metastases in a cohort of patients.

METHODS: 33 patients with 38 adrenal metastases who received percutaneous CT-guided RF ablation between 2012 to 2015 were retrospectively reviewed. The average diameter of the treated adrenal metastases was 3.0 ± 1.6 cm. The treatment outcomes, including presence of residual tumours, technical success rate, recurrence rate, and complications, were evaluated. Patients were followed up for every 3 months to monitor the progression of the disease.

RESULTS: Postoperative CT images showed the lack of tumour enhancement in 30 tumours (30/38 tumours, technical success rate = 78.9%), and residual disease was found in 7 tumours (7/37 tumours, 18.9%). The rate of residual disease was significantly lower in the group with tumour size <3 cm than the group with tumour size ≥3 cm (p = 0.025). The severe complication rate was 4.3%, and the mild complication rate was 48%, with intraoperative hypertensive crisis as the most frequently observed complication (27.3%). The follow-up data showed that 76.3% of patients had recurrence-free survival in 27.4 months.

CONCLUSION: The current study demonstrated that radiofrequency ablation is a relatively safe and effective treatment for controlling adrenal metastases, especially for patients with tumour size <3 cm. Advances in knowledge: Surgical resection of the adrenal metastases was advocated as one of the treatment options for patients. The present study showed that radiofrequency ablation is a relatively safe and effective treatment for controlling adrenal metastases.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Zhou K, Pan J, Yang N, et al. Effectiveness and safety of CT-guided percutaneous radiofrequency ablation of adrenal metastases. Br J Radiol. 2018. PMID: 29350539. doi:10.1259/bjr.20170607

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。